AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23613797 — intervention group
Group type: COMPARATOR
Intervention: Standard of care evaluation (SOC)
Number of subjects: 102
Study 23614020 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty (THA)
Number of subjects: 35
Study 23614970 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild nonproliferative diabetic retinopathy (NPDR) patients
Number of subjects: 410
Study 23614970 — intervention group
Group type: COMPARATOR
Intervention: Healthy control population
Number of subjects: 410
Study 23615181 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ridaforolimus (40 mg QDx5/wk) combined with intravenous bevacizumab (10 mg/kg Q2wk or 15 mg/kg Q3wk)
Number of subjects: 17
Study 23615181 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bevacizumab (10 mg/kg Q2wk or 15 mg/kg Q3wk)
Number of subjects: 17
Study 23615219 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 0
Study 23615219 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 23615312 — intervention group
Group type: EXPERIMENTAL
Intervention: Single urine albumin/creatinine ratio (ACR) determination
Number of subjects: 182
Study 23615312 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria presence
Number of subjects: 182
Study 23615312 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria
Number of subjects: 182
Study 23615312 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 count <200 cells/μl
Number of subjects: 182
Study 23615312 — intervention group
Group type: EXPERIMENTAL
Intervention: Current ritonavir exposure
Number of subjects: 182
Study 23615831 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm children
Number of subjects: 479
Study 23616149 — intervention group
Group type: EXPERIMENTAL
Intervention: Total osteocalcin (OC)
Number of subjects: 63
Study 23616149 — intervention group
Group type: EXPERIMENTAL
Intervention: Undercarboxylated osteocalcin (unOC)
Number of subjects: 63
Study 23616510 — intervention group
Group type: EXPERIMENTAL
Intervention: Scripted messages delivered by nurses and radio
Number of subjects: 266
Study 23617211 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of clean cloth for delivery
Number of subjects: 17
Study 23617211 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing and wearing of gloves by birth attendants
Number of subjects: 17
Study 23617211 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of new razor blade to cut the cord
Number of subjects: 17
Study 23617211 — intervention group
Group type: EXPERIMENTAL
Intervention: Tying the cord with used thread
Number of subjects: 17
Study 23617211 — intervention group
Group type: EXPERIMENTAL
Intervention: Applying something to the cord
Number of subjects: 17
Study 23617211 — intervention group
Group type: EXPERIMENTAL
Intervention: Family members inserting hands into vagina to check labor progress
Number of subjects: 17
Study 23617211 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of unclean thread for cord tying
Number of subjects: 17
Study 23617211 — intervention group
Group type: EXPERIMENTAL
Intervention: Putting substances on the cord
Number of subjects: 17
Study 23617211 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of clean thread as cord-tie
Number of subjects: 17
Study 23617513 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CT angiography
Number of subjects: 105
Study 23617513 — intervention group
Group type: EXPERIMENTAL
Intervention: CT perfusion
Number of subjects: 105
Study 23617513 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cardiac CT and CT perfusion
Number of subjects: 105
Study 23617618 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy (HYP)
Number of subjects: 44
Study 23617618 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (EDU)
Number of subjects: 44
Study 23617618 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 44
Study 23617626 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive malaria screening and prompt treatment
Number of subjects: 1218
Study 23617744 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy as per evidence-based guidelines for stroke prevention in AF
Number of subjects: 4582
Study 23617744 — intervention group
Group type: EXPERIMENTAL
Intervention: CHADS2 and CHA2DS2VASC stroke risk scores
Number of subjects: 4582
Study 23617744 — intervention group
Group type: EXPERIMENTAL
Intervention: HAS-BLED bleeding risk score
Number of subjects: 4582
Study 23618062 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]FEDAA1106 PET imaging in MS patients
Number of subjects: 9
Study 23618062 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection of VT and SUV images in MS patients
Number of subjects: 9
Study 23618062 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]FEDAA1106 as a PET radioligand
Number of subjects: 9
Study 23618318 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention to reduce the incidence of sexually transmitted disease and unsafe sexual behaviors
Number of subjects: 48
Study 23620058 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginate-encapsulated human islet cell implants
Number of subjects: 16
Study 23620058 — intervention group
Group type: COMPARATOR
Intervention: Free grafts of human islet cells
Number of subjects: 16
Study 23620091 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative best-corrected visual acuity (BCVA)
Number of subjects: 23
Study 23620091 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative junction line integrity between inner and outer segments of photoreceptors (IS/OS)
Number of subjects: 23
Study 23620091 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative VA
Number of subjects: 23
Study 23620091 — intervention group
Group type: EXPERIMENTAL
Intervention: Foveal thickness
Number of subjects: 23
Study 23620091 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative outer retinal layer integrity
Number of subjects: 23
Study 23620192 — intervention group
Group type: EXPERIMENTAL
Intervention: Children who screened positive for PTSD
Number of subjects: 167
Study 23620192 — intervention group
Group type: EXPERIMENTAL
Intervention: Children whose mothers had PTSD
Number of subjects: 167
Study 23620192 — intervention group
Group type: COMPARATOR
Intervention: Children who did not screen positive for PTSD
Number of subjects: 167
Study 23620304 — intervention group
Group type: EXPERIMENTAL
Intervention: Excess Skin (ES)
Number of subjects: 26
Study 23620574 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg
Number of subjects: 483
Study 23620574 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg
Number of subjects: 483
Study 23620574 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 483
Study 23620574 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 483
Study 23620574 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytogenetic response
Number of subjects: 483
Study 23620742 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Doppler Flowmetry (LDF)
Number of subjects: 15
Study 23620742 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Speckle Contrast Imaging (LSCI)
Number of subjects: 15
Study 23621514 — intervention group
Group type: EXPERIMENTAL
Intervention: SNS01 (Ectoin Rhinitis nasal spray)
Number of subjects: 0
Study 23621514 — intervention group
Group type: COMPARATOR
Intervention: BNO-101 (Sinupret forte dragées)
Number of subjects: 0
Study 23622855 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar Disorder (BD)
Number of subjects: 109
Study 23622855 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention-Deficit/Hyperactivity Disorder (ADHD)
Number of subjects: 109
Study 23622855 — intervention group
Group type: COMPARATOR
Intervention: Typically Developing Controls (TDC)
Number of subjects: 109
Study 23622977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballooned-tip PEGJ feeding tubes
Number of subjects: 7
Study 23623397 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab 600 mg intravenous weekly for 4 weeks, 900 mg in the fifth week, and then 900 mg every 2 weeks for 48 weeks.
Number of subjects: 14
Study 23623397 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab treatment
Number of subjects: 14
Study 23623397 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab withdrawal
Number of subjects: 14
Study 23623559 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential FISH analyses of immunomagnetically enriched CD34+ peripheral blood cells
Number of subjects: 360
Study 23623559 — intervention group
Group type: COMPARATOR
Intervention: Conventional chromosome banding (CCB) analysis of bone marrow metaphases
Number of subjects: 360
Study 23624172 — intervention group
Group type: EXPERIMENTAL
Intervention: Active weight gain prevention intervention
Number of subjects: 272
Study 23624172 — intervention group
Group type: COMPARATOR
Intervention: Alternative intervention focused on oral health
Number of subjects: 272
Study 23624209 — intervention group
Group type: EXPERIMENTAL
Intervention: CD30 positive cases after chemotherapy
Number of subjects: 49
Study 23624209 — intervention group
Group type: COMPARATOR
Intervention: CD30 negative cases after chemotherapy
Number of subjects: 49
Study 23624209 — intervention group
Group type: EXPERIMENTAL
Intervention: After first line treatment in CD30 positive cases
Number of subjects: 49
Study 23624209 — intervention group
Group type: COMPARATOR
Intervention: After first line treatment in CD30 negative cases
Number of subjects: 49
Study 23624993 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (0.6, 1.2, or 1.8 mg daily for 12 weeks)
Number of subjects: 40
Study 23624993 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 12 weeks)
Number of subjects: 40
Study 23625112 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP of 135-139 mmHg and DBP of 74-76 mmHg
Number of subjects: 34009
Study 23625112 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP of 142-150 mmHg and DBP of 78-79 mmHg
Number of subjects: 34009
Study 23625112 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 34009
Study 23625132 — intervention group
Group type: EXPERIMENTAL
Intervention: VolumeView™-CCO method
Number of subjects: 72
Study 23625132 — intervention group
Group type: COMPARATOR
Intervention: PiCCO2™-CCO pulse wave analysis
Number of subjects: 72
Study 23626752 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin treatment
Number of subjects: 3909
Study 23626901 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (r-hGH) therapy (0.033 mg/kg daily for 4 weeks)
Number of subjects: 205
Study 23627193 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 226
Study 23627666 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0
Study 23627920 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine
Number of subjects: 155
Study 23628375 — intervention group
Group type: EXPERIMENTAL
Intervention: Catch-up growth
Number of subjects: 483
Study 23628375 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) use
Number of subjects: 483
Study 23628375 — intervention group
Group type: COMPARATOR
Intervention: Normal height (NH) group
Number of subjects: 483
Study 23629519 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported CRC screening behavior (colonoscopy, sigmoidoscopy, fecal occult blood testing)
Number of subjects: 2138
Study 23629519 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully adjusted model for CRC screening
Number of subjects: 2138
Study 23629519 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual source of care
Number of subjects: 2138
Study 23629714 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZI) 500 mg once a day for 3 days
Number of subjects: 12
Study 23629822 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG-CoA reductase inhibitors (statins)
Number of subjects: 0
Study 23629822 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0
Study 23629822 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 23630200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib (30 mg once daily in 28-day cycles)
Number of subjects: 46
Study 23630200 — intervention group
Group type: COMPARATOR
Intervention: Cediranib
Number of subjects: 46
Study 23630218 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated electronic systems for real-time data collection
Number of subjects: 44
Study 23631460 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 166
Study 23631460 — intervention group
Group type: COMPARATOR
Intervention: Control (anesthetic agents only)
Number of subjects: 166
Study 23631814 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation management in 2010 (including increased use of noninvasive positive-pressure ventilation, decreased tidal volume, and increased positive end-expiratory pressure)
Number of subjects: 18302
Study 23631814 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted mechanical ventilation management in 2010
Number of subjects: 18302
Study 23632474 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg once daily plus intravenous paclitaxel 80 mg m(-2) on days 1, 8, and 15 of each 28-day cycle
Number of subjects: 102
Study 23632636 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitic acid (PA) treatment
Number of subjects: 0
Study 23632636 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFα treatment
Number of subjects: 0
Study 23632636 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PA and TNFα treatment
Number of subjects: 0
Study 23632636 — intervention group
Group type: EXPERIMENTAL
Intervention: Knockdown of EGR-1
Number of subjects: 0
Study 23632636 — intervention group
Group type: COMPARATOR
Intervention: Term placenta from obese women
Number of subjects: 0
Study 23632904 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (0.03-0.06 mg/kg/day) for >12 months (mean duration 4.1 years)
Number of subjects: 41
Study 23632904 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 41
Study 23633099 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose 3F8 (SD-3F8) (20 mg/m2 daily for 5 days per cycle)
Number of subjects: 215
Study 23633099 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose 3F8 (HD-3F8) (80 mg/m2 daily for 5 days per cycle)
Number of subjects: 215
Study 23633099 — intervention group
Group type: COMPARATOR
Intervention: Prior brain irradiation (external-beam radiotherapy)
Number of subjects: 215
Study 23633099 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall anti-GD2 MoAb immunotherapy
Number of subjects: 215
Study 23633215 — intervention group
Group type: EXPERIMENTAL
Intervention: STN-DBS (Stim-ON)
Number of subjects: 8
Study 23633215 — intervention group
Group type: EXPERIMENTAL
Intervention: STN-DBS (Stim-OFF)
Number of subjects: 8
Study 23633215 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8
Study 23633404 — intervention group
Group type: EXPERIMENTAL
Intervention: H5 DNA prime followed by H5N1 monovalent inactivated vaccine boost at intervals of 4, 8, 12, 16, or 24 weeks
Number of subjects: 0
Study 23633404 — intervention group
Group type: COMPARATOR
Intervention: 2 doses of H5N1 monovalent inactivated vaccine
Number of subjects: 0
Study 23633404 — intervention group
Group type: EXPERIMENTAL
Intervention: H5 DNA prime followed by H5N1 monovalent inactivated vaccine boost at intervals of ≥12 weeks
Number of subjects: 0
Study 23633657 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucomatous eyes with progression
Number of subjects: 62
Study 23633657 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucomatous eyes without progression
Number of subjects: 62
Study 23633657 — intervention group
Group type: COMPARATOR
Intervention: Healthy eyes
Number of subjects: 62
Study 23633663 — intervention group
Group type: EXPERIMENTAL
Intervention: cSLO FAF imaging
Number of subjects: 22
Study 23634291 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine, oxaliplatin, and bevacizumab
Number of subjects: 38
Study 23635417 — intervention group
Group type: EXPERIMENTAL
Intervention: Decide2Quit.org (Google-referred smokers)
Number of subjects: 605
Study 23635417 — intervention group
Group type: EXPERIMENTAL
Intervention: Google smokers
Number of subjects: 605
Study 23635417 — intervention group
Group type: COMPARATOR
Intervention: Medical-referred smokers
Number of subjects: 605
Study 23635417 — intervention group
Group type: COMPARATOR
Intervention: Dental-referred smokers
Number of subjects: 605
Study 23635743 — intervention group
Group type: EXPERIMENTAL
Intervention: Massively parallel sequencing of maternal plasma DNA
Number of subjects: 113
Study 23635743 — intervention group
Group type: EXPERIMENTAL
Intervention: Massively parallel sequencing for trisomy 21 (T21)
Number of subjects: 113
Study 23635743 — intervention group
Group type: EXPERIMENTAL
Intervention: Massively parallel sequencing for trisomy 18 (T18)
Number of subjects: 113
Study 23635743 — intervention group
Group type: EXPERIMENTAL
Intervention: Massively parallel sequencing for trisomy 13 (T13)
Number of subjects: 113
Study 23635743 — intervention group
Group type: EXPERIMENTAL
Intervention: Massively parallel sequencing for monosomy X
Number of subjects: 113
Study 23635743 — intervention group
Group type: EXPERIMENTAL
Intervention: Massively parallel sequencing for whole chromosome aneuploidy
Number of subjects: 113
Study 23635746 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ultrasound-guided radiofrequency volumetric thermal ablation
Number of subjects: 135
Study 23636237 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant rs838145
Number of subjects: 71393
Study 23636237 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant rs1421085 (FTO)
Number of subjects: 71393
Study 23636240 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 409
Study 23636240 — intervention group
Group type: EXPERIMENTAL
Intervention: FADS SNP rs1535 (homozygous carriers of the minor allele)
Number of subjects: 409
Study 23636240 — intervention group
Group type: EXPERIMENTAL
Intervention: FADS SNP rs174448 (minor allele carriers)
Number of subjects: 409
Study 23636240 — intervention group
Group type: EXPERIMENTAL
Intervention: FADS SNP rs174575 (minor allele carriers)
Number of subjects: 409
Study 23636240 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish intake
Number of subjects: 409
Study 23636240 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish intake at 3 years
Number of subjects: 409
Study 23636448 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 400 mg plus ketoconazole 400 mg once daily for 5 days after 7 days of pazopanib 400 mg alone.
Number of subjects: 34
Study 23636448 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg plus esomeprazole 40 mg once daily for 5 days after 7 days of pazopanib 800 mg alone.
Number of subjects: 34
Study 23636603 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitators of CPR training
Number of subjects: 24
Study 23636603 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to taking CPR training
Number of subjects: 24
Study 23636603 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitators of providing CPR
Number of subjects: 24
Study 23636603 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to providing CPR
Number of subjects: 24
Study 23636645 — intervention group
Group type: EXPERIMENTAL
Intervention: Paxman PSC-2 machine (PAX)
Number of subjects: 238
Study 23636645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold cap (CC)
Number of subjects: 238
Study 23636645 — intervention group
Group type: COMPARATOR
Intervention: No cooling
Number of subjects: 238
Study 23636645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling (PAX and CC combined)
Number of subjects: 238
Study 23636645 — intervention group
Group type: EXPERIMENTAL
Intervention: PAX and CC
Number of subjects: 238
Study 23636668 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated hemolysis (LDH levels ≥1.5 times the upper limit of normal)
Number of subjects: 301
Study 23636668 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of LDH ≥1.5 × ULN with clinical symptoms (abdominal pain, chest pain, dyspnea, hemoglobinuria)
Number of subjects: 301
Study 23636668 — intervention group
Group type: EXPERIMENTAL
Intervention: TE occurrence
Number of subjects: 301
Study 23636870 — intervention group
Group type: EXPERIMENTAL
Intervention: Amigo™ remote catheter system
Number of subjects: 181
Study 23637029 — intervention group
Group type: EXPERIMENTAL
Intervention: LAP-BAND System
Number of subjects: 149
Study 23637051 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox taken with soft food at breakfast
Number of subjects: 0
Study 23637051 — intervention group
Group type: COMPARATOR
Intervention: Deferasirox taken as per label (empty stomach with water, apple juice, or orange juice)
Number of subjects: 0
Study 23637051 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox administration modes during assessment phase
Number of subjects: 0
Study 23638111 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Decision Making (SDM) training
Number of subjects: 244
Study 23638111 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SDM training)
Number of subjects: 244
Study 23638111 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (with SDM training)
Number of subjects: 244
Study 23638197 — intervention group
Group type: EXPERIMENTAL
Intervention: Chagas heart disease
Number of subjects: 342
Study 23638197 — intervention group
Group type: COMPARATOR
Intervention: Non-Chagas cardiomyopathy
Number of subjects: 342
Study 23638197 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone use
Number of subjects: 342
Study 23638197 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker use
Number of subjects: 342
Study 23638197 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEDD
Number of subjects: 342
Study 23638197 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine clearance
Number of subjects: 342
Study 23638448 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin, flexible dose 1 to 6 mg/d
Number of subjects: 23
Study 23639146 — intervention group
Group type: COMPARATOR
Intervention: OROS methylphenidate (extended-release), robust dosing, duration up to 12 months
Number of subjects: 0
Study 23639146 — intervention group
Group type: COMPARATOR
Intervention: Non-ADHD comparison group
Number of subjects: 0